CAS: 1072-68-0; 1,4-Dimethylpyrazole

相似化合物

121669-69-0 66121-71-9 39806-89-8

上下游产品

CAS号7554-65-6 4-甲基吡唑 | CAS号74-88-4 碘甲烷 | CAS号123-91-1 1,4-二氧六环 | CAS号102-85-2 亚磷酸三丁酯 | CAS号10602-37-6 1,1,3,3-四乙氧基-2-甲基丙烷 | CAS号7339-53-9 methyl-Hydrazin... | CAS号56-23-5 四氯化碳 | CAS号160886-90-8 1H-Pyrazole-5-c... | CAS号5952-92-1 1-甲基吡唑-4-甲酸 | CAS号127842-11-9 5-chloro-1,4-di... | CAS号127842-10-8 3,5-Dichloro-1,... | CAS号1047644-76-7 1,4-二甲基-5-(4,4,...

4-甲基吡唑 以100%的收率获得1,4-二甲基吡唑
参考文献:N-Alkylation Method Of Pyrazole
标题:N-Alkylation Method Of Pyrazole
摘要:一种吡唑的n-烷基化方法,其中(III)是由(I)和(II)生成的,其特征在于使用晶体状的铝硅酸盐或晶体状的铝磷酸盐作为催化剂:##str1##其中r.Sup.1,R.Sup.2和r.Sup.3中的每一个代表氢,烷基,烯基或苯基,R代表烷基,Q代表氢,烷基或coor.这是一种工业上非常有用的方法,因为在温和的反应条件下可以高产地得到(III),并且不会产生包括盐在内的副产物.

专利信息

专利号:US-5191087-A
优先权日:1991-07-24
标 题 :Process for the synthesis of 1,4-disubstituted pyrazoles
发明人：ALCARAZ JEAN-MARIE; LECACHEUR MARYSE; ROBIN YVES
权利人:POUDRES & EXPLOSIFS STE NALE
摘要:The present invention relates to a process for the synthesis of 1,4-disubstituted pyrazoles. A monosubstituted hydrazine is reacted with the product of reaction of an acetal with an N-substituted halomethyliminium salt, preferably N,N-dimethylchloromethyliminium chloride. n The 1,4-disubstituted pyrazoles are, in particular, important intermediates in the synthesis of herbicides or drugs.

专利号:WO-2023086801-A1
优先权日:2021-11-09
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-10000487-B2
优先权日:2015-11-20
标 题 :Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
发明人：SPRENGELER PAUL A; REICH SEIGFRIED H; WEBBER STEPHEN E; ERNST JUSTIN T
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. n nFor Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:WO-2015091558-A1
优先权日:2013-12-16
标 题 :Quinoline derivates as precursors of 18f-labelled radiotracers and radiolabelling method
发明人：THANING MIKKEL JACOB; WYNN DUNCAN GEORGE; FAIRWAY STEVEN MICHAEL; NAIRNE ROBERT JAMES; FURUMOTO SHOZO
权利人:GE HEALTHCARE LTD
摘要:The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to precursors for the preparation of 18 F-labelled tau imaging radiotracers. The invention provides alternative methods of preparation of such precursors, with fewer process steps. Also provided are protected quinoline intermediates useful in the synthesis, and methods of 18 F-radiofluorination using precursors prepared via the method of the invention.